---
title: "FDA Grants Breakthrough Therapy Designation to Relay Therapeutics' Zovegalisib for Advanced Breast Cancer"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274650361.md"
datetime: "2026-02-03T12:00:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274650361.md)
  - [en](https://longbridge.com/en/news/274650361.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274650361.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274650361.md) | [English](https://longbridge.com/en/news/274650361.md)


# FDA Grants Breakthrough Therapy Designation to Relay Therapeutics' Zovegalisib for Advanced Breast Cancer

Relay Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to zovegalisib (RLY-2608) in combination with fulvestrant for the treatment of adults with PIK3CA mutant, hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer following recurrence or progression after treatment with a CDK4/6 inhibitor. The designation is supported by clinical data from the Phase 1⁄2 ReDiscover trial and is intended to accelerate the development and review of therapies for serious conditions with potential for substantial improvement over existing treatments. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9647240-en) on February 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Relay Therapeutics (RLAY.US)](https://longbridge.com/zh-HK/quote/RLAY.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)

## 相關資訊與研究

- [BUZZ-Caribou rises on FDA's regenerative medicine advanced therapy tag for blood cancer therapy](https://longbridge.com/zh-HK/news/281186075.md)
- [MAIA's Phase 2 Trial Shows Eight Lung Cancer Patients Surpassing Two Years Of Survival](https://longbridge.com/zh-HK/news/281329946.md)
- [SeaStar Medical Highlights New Positive QUELIMMUNE Data In Pediatric AKI](https://longbridge.com/zh-HK/news/281121555.md)
- [Assessing Relay Therapeutics (RLAY) Valuation After New ReDiscover Trial Data And FDA Breakthrough Status](https://longbridge.com/zh-HK/news/281081012.md)
- [Oculis' Privosegtor Granted Priority Medicines Designation in Europe for Optic Neuritis](https://longbridge.com/zh-HK/news/281158152.md)